The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Clonal hematopoiesis and hematological malignancy
Abstract
Clonal hematopoiesis (CH), the expansion of hematopoietic stem cells and their progeny driven by somatic mutations in leukemia-associated genes, is a common phenomenon that rises in prevalence with advancing age to affect most people older than 70 years. CH remains subclinical in most carriers, but, in a minority, it progresses to a myeloid neoplasm, such as acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasm. Over the last decade, advances in our understanding of CH, its molecular landscape, and the risks associated with different driver gene mutations have culminated in recent developments that allow for a more precise estimation of myeloid neoplasia risk in CH carriers. In turn, this is leading to the development of translational and clinical programs to intercept and prevent CH from developing into myeloid neoplasia. Here, we give an overview of the spectrum of CH driver mutations, what is known about their pathophysiology, and how this informs the risk of incident myeloid malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311347 · Cited by 2,003
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Scotti, M. M., & Swanson, M. S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.3 · Cited by 1,163
Dnmt3a is essential for hematopoietic stem cell differentiation
Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T. L., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,085
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · cited 1×
“The structural similarity between α -KG and 2-HG allows the latter to occupy substrate-binding sites on TET2 and other α -KG–dependent dioxygenases, including prolyl hydroxylases and histone demethylases, inhibiting their enzymatic function (61, 62).”
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
Prediction of acute myeloid leukaemia risk in healthy individuals
Abelson, S., Collord, G., Ng, S. W. K., Weissbrod, O., Mendelson Cohen, N., Niemeyer, E., Barda, N., Zuzarte, P. C., Heisler, L., Sundaravadanam, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0317-6 · Cited by 850
Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation
Jia, D., Jurkowska, R. Z., Zhang, X., Jeltsch, A., & Cheng, X. (2007) · Nature · doi:10.1038/nature06146 · Cited by 846
Thymine DNA Glycosylase Can Rapidly Excise 5-Formylcytosine and 5-Carboxylcytosine
Maiti, A., & Drohat, A. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c111.284620 · Cited by 828
Yan, X.-J., Xu, J., Gu, Z.-H., Pan, C.-M., Lu, G., Shen, Y., Shi, J.-Y., Zhu, Y.-M., Tang, L., Zhang, X.-W., et al. (2011) · Nature Genetics · doi:10.1038/ng.788 · Cited by 813
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Zink, F., Stacey, S. N., Norddahl, G. L., Frigge, M. L., Magnusson, O. T., Jonsdottir, I., Thorgeirsson, T. E., Sigurdsson, A., Gudjonsson, S. A., Gudmundsson, J., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769869 · Cited by 777
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Bolton, K. L., Ptashkin, R. N., Gao, T., Braunstein, L., Devlin, S. M., Kelly, D., Patel, M., Berthon, A., Syed, A., Yabe, M., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00710-0 · Cited by 751
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Young, A. L., Challen, G. A., Birmann, B. M., & Druley, T. E. (2016) · Nature Communications · doi:10.1038/ncomms12484 · Cited by 692
Li, Z., Cai, X., Cai, C.-L., Wang, J., Zhang, W., Petersen, B. E., Yang, F.-C., & Xu, M. (2011) · Blood · doi:10.1182/blood-2010-12-325241 · Cited by 671
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
Grinfeld, J., Nangalia, J., Baxter, E. J., Wedge, D. C., Angelopoulos, N., Cantrill, R., Godfrey, A. L., Papaemmanuil, E., Gundem, G., MacLean, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716614 · Cited by 631
Somatic mutations precede acute myeloid leukemia years before diagnosis
Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619
Ko, M., Bandukwala, H. S., An, J., Lamperti, E. D., Thompson, E. C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S. B., & Rao, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112317108 · Cited by 616
Population dynamics of normal human blood inferred from somatic mutations
Lee-Six, H., Øbro, N. F., Shepherd, M. S., Grossmann, S., Dawson, K., Belmonte, M., Osborne, R. J., Huntly, B. J. P., Martincorena, I., Anderson, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0497-0 · Cited by 604
Detectable clonal mosaicism from birth to old age and its relationship to cancer
Laurie, C. C., Laurie, C. A., Rice, K., Doheny, K. F., Zelnick, L. R., McHugh, C. P., Ling, H., Hetrick, K. N., Pugh, E. W., Amos, C., et al. (2012) · Nature Genetics · doi:10.1038/ng.2271 · Cited by 594
Detectable clonal mosaicism and its relationship to aging and cancer
Jacobs, K. B., Yeager, M., Zhou, W., Wacholder, S., Wang, Z., Rodriguez-Santiago, B., Hutchinson, A., Deng, X., Liu, C., Horner, M.-J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2270 · Cited by 589
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C.-W., Ramakrishnan, A., Li, Y., Chung, Y. R., Micol, J.-B., Murphy, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.006 · Cited by 575
Clonal dynamics of haematopoiesis across the human lifespan
Mitchell, E., Spencer Chapman, M., Williams, N., Dawson, K. J., Mende, N., Calderbank, E. F., Jung, H., Mitchell, T., Coorens, T. H. H., Spencer, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04786-y · Cited by 544
Self-citationNonrandom X-inactivation patterns in normal females: lyonization ratios vary with age
Busque, L., Mio, R., Mattioli, J., Brais, E., Blais, N., Lalonde, Y., Maragh, M., & Gilliland, D. (1996) · Blood · doi:10.1182/blood.v88.1.59.59 · Cited by 543
Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis
McKerrell, T., Park, N., Moreno, T., Grove, C. S., Ponstingl, H., Stephens, J., Crawley, C., Craig, J., Scott, M. A., Hodkinson, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.005 · Cited by 534
Self-citationDNMT3A in haematological malignancies
Yang, L., Rau, R. E., & Goodell, M. A. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3895 · Cited by 533
Replication-Dependent Loss of 5-Hydroxymethylcytosine in Mouse Preimplantation Embryos
Inoue, A., & Zhang, Y. (2011) · Science · doi:10.1126/science.1212483 · Cited by 489
Gibson, C. J., Lindsley, R. C., Tchekmedyian, V., Mar, B. G., Shi, J., Jaiswal, S., Bosworth, A., Francisco, L., He, J., Bansal, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6712 · Cited by 480
Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation
Hashimoto, H., Liu, Y., Upadhyay, A. K., Chang, Y., Howerton, S. B., Vertino, P. M., Zhang, X., & Cheng, X. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks155 · Cited by 477
Russler-Germain, D. A., Spencer, D. H., Young, M. A., Lamprecht, T. L., Miller, C. A., Fulton, R., Meyer, M. R., Erdmann-Gilmore, P., Townsend, R. R., Wilson, R. K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.010 · Cited by 452 · cited 1×
“Although DNMT3A-R882 mutations are almost always heterozygous, the mutant protein was proposed to exert a dominant-negative effect by dimerizing with its wild-type counterpart and preventing formation of the more active tetrameric complex (25, 36), although this has been disputed (37).”
The evolutionary dynamics and fitness landscape of clonal hematopoiesis
Watson, C. J., Papula, A. L., Poon, G. Y. P., Wong, W. H., Young, A. L., Druley, T. E., Fisher, D. S., & Blundell, J. R. (2020) · Science · doi:10.1126/science.aay9333 · Cited by 444
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
Hsu, J. I., Dayaram, T., Tovy, A., De Braekeleer, E., Jeong, M., Wang, F., Zhang, J., Heffernan, T. P., Gera, S., Kovacs, J. J., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.10.004 · Cited by 425
Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations
Loh, P.-R., Genovese, G., Handsaker, R. E., Finucane, H. K., Reshef, Y. A., Palamara, P. F., Birmann, B. M., Talkowski, M. E., Bakhoum, S. F., McCarroll, S. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0321-x · Cited by 423
Cai, Z., Kotzin, J. J., Ramdas, B., Chen, S., Nelanuthala, S., Palam, L. R., Pandey, R., Mali, R. S., Liu, Y., Kelley, M. R., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.013 · Cited by 394
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
Lu, X., Nannenga, B., & Donehower, L. A. (2005) · Genes & Development · doi:10.1101/gad.1291305 · Cited by 389
Obeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380
Kar, S. P., Quiros, P. M., Gu, M., Jiang, T., Mitchell, J., Langdon, R., Iyer, V., Barcena, C., Vijayabaskar, M. S., Fabre, M. A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01121-z · Cited by 377
Self-citationThe longitudinal dynamics and natural history of clonal haematopoiesis
Fabre, M. A., de Almeida, J. G., Fiorillo, E., Mitchell, E., Damaskou, A., Rak, J., Orrù, V., Marongiu, M., Chapman, M. S., Vijayabaskar, M. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04785-z · Cited by 374
Self-citationDnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells
Challen, G. A., Sun, D., Mayle, A., Jeong, M., Luo, M., Rodriguez, B., Mallaney, C., Celik, H., Yang, L., Xia, Z., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.06.018 · Cited by 354
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Chachoua, I., Pecquet, C., El-Khoury, M., Nivarthi, H., Albu, R.-I., Marty, C., Gryshkova, V., Defour, J.-P., Vertenoeil, G., Ngo, A., et al. (2016) · Blood · doi:10.1182/blood-2015-11-681932 · Cited by 349
Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
Weeks, L. D., Niroula, A., Neuberg, D., Wong, W., Lindsley, R. C., Luskin, M. R., Berliner, N., Stone, R. M., DeAngelo, D. J., Soiffer, R. J., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200310 · Cited by 346
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Abdel-Wahab, O. I., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y. R., Kuscu, C., Hricik, T., Ndiaye‐Lobry, D., LaFave, L. M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131141 · Cited by 337
Large conserved domains of low DNA methylation maintained by Dnmt3a
Jeong, M., Sun, D., Luo, M., Huang, Y., Challen, G. A., Rodriguez, B., Zhang, X., Chavez, L., Wang, H., Hannah, R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2836 · Cited by 324
Distinction of lymphoid and myeloid clonal hematopoiesis
Niroula, A., Sekar, A., Murakami, M. A., Trinder, M., Agrawal, M., Wong, W. J., Bick, A. G., Uddin, M. M., Gibson, C. J., Griffin, G. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01521-4 · Cited by 322
Kwok, B., Hall, J. M., Witte, J. S., Xu, Y., Reddy, P., Lin, K., Flamholz, R., Dabbas, B., Yung, A., Al-Hafidh, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-667063 · Cited by 317
Araki, M., Yang, Y., Masubuchi, N., Hironaka, Y., Takei, H., Morishita, S., Mizukami, Y., Kan, S., Shirane, S., Edahiro, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-09-671172 · Cited by 299
Chen, L., Chen, J.-Y., Huang, Y.-J., Gu, Y., Qiu, J., Qian, H., Shao, C., Zhang, X., Hu, J., Li, H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2017.12.029 · Cited by 299
Elf, S., Abdelfattah, N. S., Chen, E., Perales-Patón, J., Rosen, E. A., Ko, A., Peisker, F., Florescu, N., Giannini, S., Wolach, O., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1434 · Cited by 293
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
Shirai, C. L., Ley, J. N., White, B. S., Kim, S., Tibbitts, J., Shao, J., Ndonwi, M., Wadugu, B., Duncavage, E. J., Okeyo-Owuor, T., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.008 · Cited by 287
Marty, C., Pecquet, C., Nivarthi, H., El-Khoury, M., Chachoua, I., Tulliez, M., Villeval, J., Raslová, H., Královics, R., Constantinescu, S. N., et al. (2015) · Blood · doi:10.1182/blood-2015-11-679571 · Cited by 274
Rasmussen, K. D., Jia, G., Johansen, J. V., Pedersen, M. T., Rapin, N., Bagger, F. O., Porse, B. T., Bernard, O. A., Christensen, J., & Helin, K. (2015) · Genes & Development · doi:10.1101/gad.260174.115 · Cited by 270
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome
Madan, V., Kanojia, D., Li, J., Okamoto, R., Sato‐Otsubo, A., Kohlmann, A., Sanada, M., Großmann, V., Sundaresan, J., Shiraishi, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7042 · Cited by 250
Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo
Jeong, M., Park, H. J., Celik, H., Ostrander, E. L., Reyes, J. M., Guzman, A., Rodriguez, B., Lei, Y., Lee, Y., Ding, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.025 · Cited by 243
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice
Vassiliou, G. S., Cooper, J. L., Rad, R., Li, J., Rice, S. V., Uren, A. G., Rad, L., Ellis, P., Andrews, R., Banerjee, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.796 · Cited by 240
Self-citationDNA methylation disruption reshapes the hematopoietic differentiation landscape
Izzo, F., Lee, S. C., Poran, A., Chaligne, R., Gaiti, F., Gross, B., Murali, R. R., Deochand, S. D., Ang, C., Jones, P. W., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0595-4 · Cited by 236
Lippert, É., Boissinot, M., Královics, R., et al. (2006) · Blood · doi:10.1182/blood-2006-01-013540 · Cited by 235
An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis
Abegunde, S. O., Buckstein, R., Wells, R. A., & Rauh, M. J. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2017.11.002 · Cited by 230
Monogenic and polygenic inheritance become instruments for clonal selection
Loh, P.-R., Genovese, G., & McCarroll, S. A. (2020) · Nature · doi:10.1038/s41586-020-2430-6 · Cited by 228
Vlasschaert, C., Mack, T., Heimlich, J. B., Niroula, A., Uddin, M. M., Weinstock, J. S., Sharber, B., Silver, A. J., Xu, Y., Savona, M. R., et al. (2023) · Blood · doi:10.1182/blood.2022018825 · Cited by 221
Li, J., Spensberger, D., Ahn, J. S., Anand, S., Beer, P. A., Ghevaert, C., Chen, E., Forrai, A., Scott, L. M., Ferreira, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-259747 · Cited by 212
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
Balasubramani, A., Larjo, A., Bassein, J. A., Chang, X., Hastie, R. B., Togher, S. M., Lähdesmäki, H., & Rao, A. (2015) · Nature Communications · doi:10.1038/ncomms8307 · Cited by 194
Brunetti, L., Gundry, M. C., & Goodell, M. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030320 · Cited by 186
Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking
Dawoud, A. A. Z., Tapper, W., & Cross, N. C. P. (2020) · Leukemia · doi:10.1038/s41375-020-0896-8 · Cited by 181
A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells
Kim, S. J., Zhao, H., Hardikar, S., Singh, A. K., Goodell, M. A., & Chen, T. (2013) · Blood · doi:10.1182/blood-2013-02-483487 · Cited by 180
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations
Inoue, D., Kitaura, J., Togami, K., Nishimura, K., Enomoto, Y., Uchida, T., Kagiyama, Y., Kawabata, K. C., Nakahara, F., Izawa, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70739 · Cited by 179
Loss of Asxl1 leads to myelodysplastic syndrome–like disease in mice
Wang, J., Li, Z., He, Y., Pan, F., Shi, C., Rhodes, S. D., Nguyen, L., Yuan, J., Jiang, L., Yang, X., et al. (2013) · Blood · doi:10.1182/blood-2013-05-500272 · Cited by 179
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
Yang, H., Kurtenbach, S., Guo, Y., Lohse, I., Durante, M. A., Li, J., Li, Z., Al‐Ali, H., Li, L., Chen, Z., et al. (2017) · Blood · doi:10.1182/blood-2017-06-789669 · Cited by 173
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Blood · doi:10.1182/blood-2017-06-782037 · Cited by 172
Nguyen, H. D., Leong, W. Y., Li, W., Reddy, P. N. G., Sullivan, J. D., Walter, M. J., Zou, L., & Graubert, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3970 · Cited by 169
Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling
Caiado, F., Kovtonyuk, L. V., Gonullu, N. G., Fullin, J., Boettcher, S., & Manz, M. G. (2023) · Blood · doi:10.1182/blood.2022016835 · Cited by 161
Rodriguez-Meira, A., Norfo, R., Wen, S., Chédeville, A. L., Rahman, H., O’Sullivan, J., Wang, G., Louka, E., Kretzschmar, W. W., Paterson, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01480-1 · Cited by 158 · cited 1×
“…behavior and fitness of TP53 -mutated clones, such as previous exposure to cytotoxic chemotherapy (128), presence of germline pathogenic variants (Li-Fraumeni syndrome) (149), biallelic TP53 loss (150, 151), and mutation type (with missense variants behaving in a dominant-negative manner) (125).”
Nagase, R., Inoue, D., Pastore, A., Fujino, T., Hou, H.-A., Yamasaki, N., Goyama, S., Saika, M., Kanai, A., Sera, Y., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171151 · Cited by 155
Holz-Schietinger, C., Matje, D. M., & Reich, N. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366625 · Cited by 146
Buscarlet, M., Provost, S., Zada, Y. F., Bourgoin, V., Mollica, L., Dubé, M.-P., & Busque, L. (2018) · Blood · doi:10.1182/blood-2018-01-829937 · Cited by 146
Dolatshad, H., Pellagatti, A., Liberante, F. G., Llorian, M., Repapi, E., Steeples, V., Roy, S., Scifo, L., Armstrong, R. N., Shaw, J. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.149 · Cited by 145
Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
Saiki, R., Momozawa, Y., Nannya, Y., Nakagawa, M. M., Ochi, Y., Yoshizato, T., Terao, C., Kuroda, Y., Shiraishi, Y., Chiba, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01411-9 · Cited by 145
Loberg, M. A., Bell, R. K., Goodwin, L. O., Eudy, E., Miles, L. A., SanMiguel, J. M., Young, K. A., Bergstrom, D. E., Levine, R. L., Schneider, R. K., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0368-6 · Cited by 137
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
Asada, S., Goyama, S., Inoue, D., Shikata, S., Takeda, R., Fukushima, T., Yonezawa, T., Fujino, T., Hayashi, Y., Kawabata, K. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05085-9 · Cited by 135
Multiparameter prediction of myeloid neoplasia risk
Gu, M., Kovilakam, S. C., Dunn, W. G., Marando, L., Barcena, C., Mohorianu, I., Smith, A., Kar, S. P., Fabre, M. A., Gerstung, M., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01472-1 · Cited by 132
Self-citationMupo, A., Seiler, M., Sathiaseelan, V., Pance, A., Yang, Y., Agrawal, A. A., Iorio, F., Bautista, R., Pacharne, S., Tzelepis, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.251 · Cited by 128
Self-citationMutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
Chen, S., Wang, Q., Yu, H., Capitano, M. L., Vemula, S., Nabinger, S. C., Gao, R., Yao, C., Kobayashi, M., Geng, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13542-2 · Cited by 126
Clonal hematopoiesis and risk of acute myeloid leukemia
Young, A. L., Tong, R. S., Birmann, B. M., & Druley, T. E. (2019) · Haematologica · doi:10.3324/haematol.2018.215269 · Cited by 119
Fujino, T., Goyama, S., Sugiura, Y., Inoue, D., Asada, S., Yamasaki, S., Matsumoto, A., Yamaguchi, K., Isobe, Y., Tsuchiya, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22053-y · Cited by 111
Li, J., Prins, D., Park, H. J., Grinfeld, J., Arias, C. G., Loughran, S. J., Dovey, O. M., Klampfl, T., Bennett, C., Hamilton, T. L., et al. (2017) · Blood · doi:10.1182/blood-2017-09-806356 · Cited by 110
Self-citationSplicing factor mutations in hematologic malignancies
Chen, S., Benbarche, S., & Abdel-Wahab, O. I. (2021) · Blood · doi:10.1182/blood.2019004260 · Cited by 109
Tulstrup, M., Soerensen, M., Hansen, J. W., Gillberg, L., Needhamsen, M., Kaastrup, K., Helin, K., Christensen, K., Weischenfeldt, J., & Grønbæk, K. (2021) · Nature Communications · doi:10.1038/s41467-021-26093-2 · Cited by 108
Singh, S., Ahmed, D., Dolatshad, H., Tatwavedi, D., Schulze, U., Sanchi, A., Ryley, S., Dhir, A., Carpenter, L., Watt, S. M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0753-9 · Cited by 98
Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness
Ostrander, E. L., Kramer, A. C., Mallaney, C., Celik, H., Koh, W. K., Fairchild, J., Haussler, E., Zhang, C. R. C., & Challen, G. A. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.02.011 · Cited by 94
Clough, C. A., Pangallo, J., Sarchi, M., Ilagan, J. O., North, K., Bergantinos, R., Stolla, M. C., Naru, J., Nugent, P., Kim, E. H., et al. (2021) · Blood · doi:10.1182/blood.2021012652 · Cited by 94
Qu, Y., Lennartsson, A., Gaidzik, V. I., Deneberg, S., Karimi, M., Bengtzén, S., Höglund, M., Bullinger, L., Döhner, K., & Lehmann, S. (2014) · Epigenetics · doi:10.4161/epi.29315 · Cited by 92
TET2 is essential for survival and hematopoietic stem cell homeostasis
Shide, K., Kameda, T., Shimoda, H. K., Yamaji, T., Abe, H., Kamiunten, A., Sekine, M., Hidaka, T., Katayose, K., Kubuki, Y., et al. (2012) · Leukemia · doi:10.1038/leu.2012.94 · Cited by 91
Hematologic malignancies and Li–Fraumeni syndromePreprint
Swaminathan, M., Bannon, S. A., Routbort, M. J., Naqvi, K., Kadia, T. M., Takahashi, K., Alvarado, Y., Ravandi‐Kashani, F., Patel, K. P., Champlin, R., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003210 · Cited by 89
Loizou, E., Banito, A., Livshits, G., Ho, Y.-J., Koche, R. P., Sánchez-Rivera, F. J., Mayle, A., Chen, C.-C., Kinalis, S., Bagger, F. O., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1391 · Cited by 88
Kent, D. G., Li, J., Tanna, H., Fink, J., Kirschner, K., Pask, D. C., Silber, Y., Hamilton, T. L., Sneade, R., Simons, B. D., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001576 · Cited by 87
Thrombopoietin receptor is required for the oncogenic function of CALR mutants
Nivarthi, H., Chen, D., Cleary, C. M., Kubešová, B., Jäger, R., Bogner, E., Marty, C., Pecquet, C., Vainchenker, W., Constantinescu, S. N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.32 · Cited by 87
Shide, K., Kameda, T., Yamaji, T., Sekine, M., Inada, N., Kamiunten, A., Akizuki, K., Nakamura, K., Hidaka, T., Kubuki, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.308 · Cited by 87
A novel ASXL1–OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies
Inoue, D., Fujino, T., Sheridan, P. J., Zhang, Y., Nagase, R., Horikawa, S., Li, Z., Matsui, H., Kanai, A., Saika, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0083-3 · Cited by 82
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia
Wang, L., Birch, N. W., Zhao, Z., Nestler, C. M., Kazmer, A., Shilati, A., Blake, A., Ozark, P. A., Rendleman, E. J., Zha, D., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00199-4 · Cited by 82
Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis
Stacey, S., Zink, F., Halldorsson, G. H., Stefánsdóttir, L., Gudjonsson, S. A., Einarsson, G., Hjörleifsson, G., Eiriksdottir, T., Helgadóttir, A., Björnsdóttir, G., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01555-z · Cited by 77
Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics
Uddin, M. M., Zhou, Y., Bick, A. G., Burugula, B. B., Jaiswal, S., Desai, P. M., Honigberg, M. C., Love, S.-A. M., Barac, A., Hayden, K. M., et al. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00278-9 · Cited by 75
Scheller, M., Ludwig, A. K., Göllner, S., Rohde, C., Krämer, S., Stäble, S., Janssen, M., Müller, J.-A., He, L., Bäumer, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00213-9 · Cited by 73
Inoue, D., Matsumoto, M., Nagase, R., Saika, M., Fujino, T., Nakayama, K. I., & Kitamura, T. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.11.011 · Cited by 71
ASXL1 mutation in clonal hematopoiesis
Fujino, T., & Kitamura, T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.002 · Cited by 65
Smeets, M. F. M. A., Tan, S. Y., Xu, J. J., Anande, G., Unnikrishnan, A., Chalk, A. M., Taylor, S., Pimanda, J. E., Wall, M., Purton, L. E., et al. (2018) · Blood · doi:10.1182/blood-2018-04-845602 · Cited by 63
ASXL1/2 mutations and myeloid malignancies
Medina, E. A., Delma, C. R., & Yang, F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01336-x · Cited by 59
Rossi, M., Demidov, O. N., Anderson, C. W., Appella, E., & Mazur, S. J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn888 · Cited by 57
Accumulation of DNA damage in the aged hematopoietic stem cell compartment
Beerman, I. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.11.001 · Cited by 56
Uni, M., Masamoto, Y., Sato, T., Kamikubo, Y., Arai, S., Hara, E., & Kurokawa, M. (2018) · Leukemia · doi:10.1038/s41375-018-0198-6 · Cited by 50
Cost-Effective and Scalable Clonal Hematopoiesis Assay Provides Insight into Clonal Dynamics
Mack, T., Vlasschaert, C., von Beck, K., Silver, A. J., Heimlich, J. B., Poisner, H. M., Condon, H. R., Ulloa, J., Sochacki, A. L., Spaulding, T. P., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.03.007 · Cited by 50
Emperle, M., Rajavelu, A., Reinhardt, R., Jurkowska, R. Z., & Jeltsch, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.572032 · Cited by 49
Balligand, T., Achouri, Y., Pecquet, C., Chachoua, I., Nivarthi, H., Marty, C., Vainchenker, W., Plo, I., Královics, R., & Constantinescu, S. N. (2016) · Leukemia · doi:10.1038/leu.2016.47 · Cited by 49
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
Arends, C. M., Kopp, K., Hablesreiter, R., Estrada, N., Christen, F., Moll, U. M., Zeillinger, R., Schmitt, W., Sehouli, J., Kulbe, H., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02253-3 · Cited by 49
Hsu, Y.-C., Chiu, Y., Lin, C., Kuo, Y., Hou, H., Tzeng, Y.-S., Kao, C., Chuang, P., Tseng, M., Hsiao, T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0508-x · Cited by 46
Failure to Detect Mutations in U2AF1 due to Changes in the GRCh38 Reference Sequence
Miller, C. A., Walker, J., Jensen, T. L., Hooper, W. F., Fulton, R. S., Painter, J. S., Sekeres, M. A., Ley, T. J., Spencer, D. H., Goll, J. B., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.10.013 · Cited by 40
Borrow, J., Dyer, S. A., Akiki, S. J., & Griffiths, M. (2019) · Blood · doi:10.1182/blood.2019001238 · Cited by 38
Borrow, J., Dyer, S. A., Akiki, S. J., & Griffiths, M. (2019) · Blood · doi:10.1182/blood.2019001240 · Cited by 37
Ramabadran, R., Wang, J. H., Reyes, J. M., Guzman, A. G., Gupta, S., Rosas, C., Brunetti, L., Gundry, M. C., Tovy, A., Long, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01109-9 · Cited by 35
Emperle, M., Dukatz, M., Kunert, S., Holzer, K., Rajavelu, A., Jurkowska, R. Z., & Jeltsch, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31635-8 · Cited by 34
Role of ASXL1 in hematopoiesis and myeloid diseases
Gao, X., You, X., Droin, N. M., Banaszak, L. G., Churpek, J. E., Padron, E., Geissler, K. H., Solary, É., Patnaik, M. M., & Zhang, J. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.003 · Cited by 30
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML
Burócziová, M., Daněk, P., Oravetzova, A., Chalupova, Z., Alberich-Jordà, M., & Macůrek, L. (2023) · Leukemia · doi:10.1038/s41375-023-02030-8 · Cited by 28
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
Chen, C.-W., Zhang, L., Dutta, R. K., Niroula, A., Miller, P. G., Gibson, C. J., Bick, A. G., Reyes, J. M., Lee, Y.-T., Tovy, A., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.09.011 · Cited by 28
Schick, U. M., McDavid, A., Crane, P. K., Weston, N., Ehrlich, K. J., Newton, K. M., Wallace, R. B., Bookman, E., Harrison, T. A., Aragaki, A. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059823 · Cited by 27
Köhnke, T., Nuno, K. A., Alder, C. C., Gars, E. J., Phan, P., Fan, A. C., & Majeti, R. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0235 · Cited by 23
Williams, N., Lee, J., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A. H., Godfrey, A. L., Green, A. R., Campbell, P. J., et al. (2020) · Blood · doi:10.1182/blood-2020-143813 · Cited by 22
The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function
Foskolou, I. P., Cunha, P. P., Sánchez‐López, E., Minogue, E., Nicolet, B. P., Guislain, A., Jorgensen, C., Kostidis, S., Zandhuis, N. D., Barbieri, L., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113013 · Cited by 19
NPM1 gene mutations can be confidently identified in blood DNA months before de novo AML onset
Quirós, P. M., Gu, M., Bárcena, C., Iyer, V., & Vassiliou, G. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005927 · Cited by 8
Self-citation
Metadata
- Authors
- Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2024-10-01
- Volume
- 134
- Issue
- 19
- ISSN
- 1558-8238
- Cited by
- 61
- References
- 160
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
